SABCS 2025 – Dr. Paolo Tarantino on Key SABCS Data

Dr. Paolo Tarantino reviews key SABCS updates, including lidERA with adjuvant giredestrant, HER2CLIMB-05 maintenance with tucatinib, and emerging neoadjuvant PARP inhibitor data. He also discusses negative and evolving results shaping future endocrine and metastatic strategies.